Euroasian Journal of Hepato-Gastroenterology · 2020 · 14 citations · 13 references
PharmacyInfectious DiseasesPharmacotherapyAntimicrobial PharmacotherapyInfectious Disease PharmacotherapyRespiratory PharmacotherapyAcute Medical Illness ManagementAntiviral TherapyPandemic PreparednessPandemic ResponseRespiratory DiseaseCohort Study InvestigationCovid-19-associated Acute Respiratory Distress SyndromeSars-cov-2 Antiviral TherapySars-cov-2 InfectionSevere Acute Respiratory SyndromeTreatment Of Coronavirus Infections
BACKGROUND: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared as pandemic by World Health Organization (WHO) with increasing morbidity (more than 4.6 million patients) and mortality (300,000 deaths). The world-wide target of management COVID-19 is to reduce complications with available management options; this become highly variable from country to country and even within different regions of the same country. AIM AND OBJECTIVE: This observational prospective study represents a single center study in which all patients in this cohort received almost similar medicines and care. MATERIALS AND METHODS: : 32) were positive for SARS-CoV-2 by polymerase chain reaction (PCR) with variable presenting symptoms. The management strategy included Standard of Care (SoC) and administration of hydroxychloroquine and doxycycline. Out of 32 patients, 9 patients also received favipiravir. All patients were followed until they were discharged after negativity of SARS-CoV-2 confirmed by PCR on two consecutive occasions taken within 2 days. RESULTS: No death has been recorded in this cohort of 32 patients within the study period. The average hospital staying duration was 13.9 days with a range of 8-21 days. All patients were discharged with improvement of subjective symptoms and SARS-CoV-2 negativity. The vital signs (pulse, blood pressure) as well as and levels of electrolyte and blood counts were within normal and acceptable ranges at the time of discharge. CONCLUSION: The study presented here provide and evidence of a real-life situation of management of limited numbers of COVID-19 patients at a tertiary center of Bangladesh. This study inspires optimism that proper diagnosis, establishment of effective inclusion and exclusion criteria, ensuring application of proper SoC with drugs available in Bangladesh may be a practical option for management of COVID-19 in the country. HOW TO CITE THIS ARTICLE: Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study. Euroasian J Hepato-Gastroenterol 2020;10(1):31-35.
13
Clinical Characteristics of Coronavirus Disease 2019 in China
Wei‐jie Guan, Zhengyi Ni, Yu Hu et al. · New England Journal of Medicine · 2020 · 31.2K citations · Full text
Veterinary Medicine, Infectious Diseases, Internal Medicine +10
Presumed Asymptomatic Carrier Transmission of COVID-19
Yan Bai, Tao Wei, Fei Tian et al. · JAMA · 2020 · 4.9K citations · Full text
Veterinary Medicine, Infectious Diseases, Infectious Disease Epidemiology +10
Xueting Yao, Fei Ye, Miao Zhang et al. · Clinical Infectious Diseases · 2020 · 2.8K citations · Full text
Yinghui Jin, Lin Cai, Zhenshun Cheng et al. · Military Medical Research · 2020 · 2.4K citations · Full text
Veterinary Medicine, Infectious Disease Control, Infectious Diseases +17